Despite higher levels of BCL2 in melanoma relative to CRC (Fig. 1d and Supplementary Fig. 1b) venetoclax monotherapy had no effect on viability and did not combine with selumetinib to induce apoptosis, although venetoclax marginally enhanced the combination effect of A-1155463 and selumetinib in A375 cells (Fig. 2p and Supplementary Fig. 7k, l). This evidence concerns the gene BCL2 and colorectal carcinoma.